| Literature DB >> 31067470 |
Weinan Zheng1, Wenhui Fan1, Shuang Zhang1, Pengtao Jiao2, Yingli Shang3, Liang Cui4, Madina Mahesutihan4, Jing Li1, Dayan Wang5, George Fu Gao6, Lei Sun7, Wenjun Liu4.
Abstract
Naproxen is a non-steroidal anti-inflammatory drug that has previously been shown to exert antiviral activity against influenza A virus by inhibiting nucleoprotein (NP) binding to RNA. Here, we show that naproxen is a potential broad, multi-mechanistic anti-influenza virus therapeutic, as it inhibits influenza B virus replication both in vivo and in vitro. The anti-influenza B virus activity of naproxen is more efficient than that of the commonly used neuraminidase inhibitor oseltamivir in mice. Furthermore, the NP of influenza B virus (BNP) has a higher binding affinity to naproxen than influenza A virus NP (ANP). Specifically, naproxen targets the NP at residues F209 (BNP) and Y148 (ANP). This interaction antagonizes the nuclear export of NP normally mediated by the host export protein CRM1. This study reveals a crucial mechanism of broad-spectrum anti-influenza virus activity of naproxen, suggesting that the existing drug naproxen may be used as an anti-influenza drug.Entities:
Keywords: CRM1; influenza virus; naproxen; nuclear export; nucleoprotein; vRNP
Mesh:
Substances:
Year: 2019 PMID: 31067470 DOI: 10.1016/j.celrep.2019.04.053
Source DB: PubMed Journal: Cell Rep Impact factor: 9.423